{"id":"https://openalex.org/W7204995805","doi":"https://doi.org/10.1093/oncolo/oyag312.065","title":"64 GPR65 is a Novel Therapeutic Target Associated with Immune Exhaustion in Clear Cell Renal Cell Carcinoma","display_name":"64 GPR65 is a Novel Therapeutic Target Associated with Immune Exhaustion in Clear Cell Renal Cell Carcinoma","alternate_titles":[],"publication_year":2026,"publication_date":"2026-09-01","ids":{"openalex":"https://openalex.org/W7204995805","doi":"https://doi.org/10.1093/oncolo/oyag312.065","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13535349"},"language":"en","primary_location":{"id":"doi:10.1093/oncolo/oyag312.065","doi":"https://doi.org/10.1093/oncolo/oyag312.065","is_oa":true,"landing_page_url":"https://doi.org/10.1093/oncolo/oyag312.065","pdf_url":"https://academic.oup.com/oncolo/article-pdf/31/Supplement_3/oyag312.065/70844055/oyag312.065.pdf","source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W7204995805"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://academic.oup.com/oncolo/article-pdf/31/Supplement_3/oyag312.065/70844055/oyag312.065.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5137111602","display_name":"Nicholas J. Salgia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1292894508","display_name":"Roswell Park Comprehensive Cancer Center","ror":"https://ror.org/0499dwk57","country_code":"US","type":"facility","lineage":["https://openalex.org/I1292894508"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas Salgia","raw_affiliation_strings":["Roswell Park Comprehensive Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roswell Park Comprehensive Cancer Center","institution_ids":["https://openalex.org/I1292894508"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136362101","display_name":"Koral Shah","orcid":"https://orcid.org/0000-0002-4868-8276","observed_orcids":["https://orcid.org/0000-0002-4868-8276"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Koral Shah","raw_affiliation_strings":["City of Hope Comprehensive Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope Comprehensive Cancer Center","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018028692","display_name":"Danish Memon","orcid":"https://orcid.org/0000-0002-1365-0710","observed_orcids":["https://orcid.org/0000-0002-1365-0710","https://orcid.org/0000-0002-3510-0170"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Danish Memon","raw_affiliation_strings":["Pathios Therapeutics Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pathios Therapeutics Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148973809","display_name":"Maria-Jose Oliva Martin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maria-Jose Oliva Martin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007316044","display_name":"Sumeet Ambarkhane","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sumeet Ambarkhane","raw_affiliation_strings":["Pathios Therapeutics Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pathios Therapeutics Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039719492","display_name":"Barbara Cipriani","orcid":"https://orcid.org/0000-0002-6492-3141","observed_orcids":["https://orcid.org/0000-0002-6492-3141"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Barbara Cipriani","raw_affiliation_strings":["Pathios Therapeutics Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pathios Therapeutics Ltd","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070032327","display_name":"Sumanta Monty Pal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sumanta Pal","raw_affiliation_strings":["City of Hope Comprehensive Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope Comprehensive Cancer Center","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3852,"currency":"USD","value_usd":3852},"apc_paid":{"value":3852,"currency":"USD","value_usd":3852},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"Supplement_3","first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.86080002784729,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.86080002784729,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.10189999639987946,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11297","display_name":"Ferroptosis and cancer prognosis","score":0.014800000004470348,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/clear-cell-renal-cell-carcinoma","display_name":"clear cell renal cell carcinoma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/immune-exhaustion","display_name":"immune exhaustion","score":0.9150000214576721},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.8029999732971191},{"id":"https://openalex.org/keywords/proton-sensing-receptor","display_name":"proton-sensing receptor","score":0.8349999785423279},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7289999723434448},{"id":"https://openalex.org/keywords/glycolysis","display_name":"glycolysis","score":0.6200000047683716},{"id":"https://openalex.org/keywords/tumor-acidosis","display_name":"tumor acidosis","score":0.5130000114440918},{"id":"https://openalex.org/keywords/tumor-infiltrating-immune-cells","display_name":"tumor-infiltrating immune cells","score":0.753000020980835},{"id":"https://openalex.org/keywords/adaptive-immune-response","display_name":"adaptive immune response","score":0.4560000002384186},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7839999794960022},{"id":"https://openalex.org/keywords/therapeutic-target","display_name":"therapeutic target","score":0.6650000214576721},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.8149999976158142},{"id":"https://openalex.org/keywords/single-cell-rna-sequencing","display_name":"single-cell RNA sequencing","score":0.7070000171661377},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.460999995470047},{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":0.47999998927116394}],"concepts":[{"id":"https://openalex.org/C2781278892","wikidata":"https://www.wikidata.org/wiki/Q18556340","display_name":"Clear cell renal cell carcinoma","level":3,"score":0.8482999801635742},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.713699996471405},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6155999898910522},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.5960999727249146},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.5414000153541565},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5088000297546387},{"id":"https://openalex.org/C2778560582","wikidata":"https://www.wikidata.org/wiki/Q18347894","display_name":"Clear cell","level":3,"score":0.4912000000476837},{"id":"https://openalex.org/C2781068499","wikidata":"https://www.wikidata.org/wiki/Q3242950","display_name":"Kidney cancer","level":3,"score":0.4749000072479248},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4700999855995178},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4618000090122223},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4571000039577484},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.45559999346733093},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.44269999861717224},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.38760000467300415},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.3725000023841858},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3598000109195709},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.3458000123500824},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.32910001277923584},{"id":"https://openalex.org/C162317418","wikidata":"https://www.wikidata.org/wiki/Q252857","display_name":"Transcriptome","level":4,"score":0.32199999690055847},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.3012999892234802},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.29420000314712524},{"id":"https://openalex.org/C2779256057","wikidata":"https://www.wikidata.org/wiki/Q16909647","display_name":"Tumor progression","level":3,"score":0.28999999165534973},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2838999927043915},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.27619999647140503},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.2759999930858612},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.2526000142097473}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1093/oncolo/oyag312.065","doi":"https://doi.org/10.1093/oncolo/oyag312.065","is_oa":true,"landing_page_url":"https://doi.org/10.1093/oncolo/oyag312.065","pdf_url":"https://academic.oup.com/oncolo/article-pdf/31/Supplement_3/oyag312.065/70844055/oyag312.065.pdf","source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13535349","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13535349/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13535349/pdf/oyag312.065.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncologist","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1093/oncolo/oyag312.065","doi":"https://doi.org/10.1093/oncolo/oyag312.065","is_oa":true,"landing_page_url":"https://doi.org/10.1093/oncolo/oyag312.065","pdf_url":"https://academic.oup.com/oncolo/article-pdf/31/Supplement_3/oyag312.065/70844055/oyag312.065.pdf","source":{"id":"https://openalex.org/S15523509","display_name":"The Oncologist","issn_l":"1083-7159","issn":["1083-7159","1549-490X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316295","host_organization_name":"AlphaMed Press","host_organization_lineage":["https://openalex.org/P4310316295"],"host_organization_lineage_names":["AlphaMed Press"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Oncologist","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7204995805.pdf","grobid_xml":"https://content.openalex.org/works/W7204995805.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7117307022","https://openalex.org/W3164213892","https://openalex.org/W4385454115","https://openalex.org/W4414780833","https://openalex.org/W4205717523","https://openalex.org/W3120797119","https://openalex.org/W3082141412","https://openalex.org/W4220915370","https://openalex.org/W2599487161","https://openalex.org/W4386603347"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Novel":[2,61],"therapeutic":[3],"targets":[4],"in":[5,33,58,65,88,101,110,225,271,288,311,349,356,368,380,426,452,461,481,485,529,543,580,585],"clear":[6],"cell":[7,9,194,496],"renal":[8,343],"carcinoma":[10],"(ccRCC)":[11],"remain":[12,91],"a":[13,41,245,536,552,572],"pressing":[14],"need,":[15],"particularly":[16],"for":[17,68,395,555,594],"patients":[18,69,122,205,443,556,586,595],"who":[19,557],"experience":[20,558],"progression":[21,418,559],"to":[22,55,276,294,372,424,468,474,490,524],"immune":[23,48,56,138,309,322,331,334,351],"checkpoint":[24,323],"inhibitor":[25],"(ICI)-based":[26],"therapies.":[27],"ccRCC":[28,125],"is":[29,40,551,570],"highly":[30],"glycolytic,":[31],"resulting":[32],"an":[34,449],"acidic":[35],"tumor":[36,46,273,439,521],"microenvironment":[37],"(TME).":[38],"GPR65":[39,62,87,99,106,132,247,266,314,347,363,453,483,534,550,574],"proton-sensing":[42],"receptor":[43],"enriched":[44,394],"on":[45,560],"infiltrating":[47],"cells":[49,460],"that":[50,463,476],"has":[51],"ultimately":[52],"been":[53],"connected":[54],"dysfunction":[57],"the":[59,77,95,102,544],"TME.":[60,104,546],"inhibitors":[63],"are":[64],"clinical":[66,84,118,360],"development":[67],"with":[70,123,133,153,185,206,244,319,353,408,421,510,582,587,596],"RCC":[71,89,103,207,240,272,291,338,486,545],"and":[72,83,117,128,140,160,173,227,242,284,325,340,378,382,457,504,517,519,539],"other":[73],"solid":[74,588],"tumors.":[75],"However,":[76,434],"expression":[78,107,178,250,260,267,315,320,355,364,454,492],"patterns,":[79],"associated":[80],"TME":[81,143,389],"phenotypes,":[82],"implications":[85],"of":[86,98,131,204,252,307,321,328,337,437,493,512],"tumors":[90,241,253,292,339,370,374,462],"uncharacterized,":[92],"as":[93,163,577],"does":[94],"biological":[96],"impact":[97],"inhibition":[100,484],"Methods":[105],"was":[108,199,268,285,365,391],"interrogated":[109],"The":[111,385,563],"Cancer":[112,148,221],"Genome":[113],"Atlas":[114],"(TCGA)":[115],"KIRC":[116],"trial":[119,361,568],"cohorts":[120,203,593],"comprising":[121],"metastatic":[124],"(IMmotion151,":[126],"Javelin101,":[127,383],"HCRN-GU16-260).":[129],"Associations":[130],"clinicopathological":[134],"features,":[135],"co-expressed":[136],"genes,":[137],"infiltrates,":[139],"IMmotion151":[141,381,386],"NMF":[142,388],"phenotypes":[144],"(Motzer":[145],"et":[146,209,214,219],"al.":[147,210,215,220],"Cell.":[149],"2020)":[150],"were":[151,169,236,254],"assessed":[152,255],"Pearson":[154],"correlation":[155],"coefficients,":[156],"Mann-Whitney":[157],"U":[158],"tests,":[159],"Chi-square":[161],"tests":[162],"appropriate.":[164],"Tumors":[165],"within":[166],"each":[167],"cohort":[168],"stratified":[170],"into":[171],"GPR65-High":[172,312,396,401],"-Low":[174],"groups":[175],"by":[176,256,333],"median":[177],"value.":[179],"Survival":[180],"analysis":[181,303,345,436],"employed":[182],"Kaplan-Meier":[183],"estimates":[184],"comparisons":[186],"performed":[187],"using":[188],"Cox":[189],"proportional":[190],"hazard":[191],"models.":[192,532],"Single":[193],"RNA":[195],"sequencing":[196],"(scRNAseq)":[197],"data":[198,548],"analyzed":[200],"from":[201,238,441],"three":[202],"(Zhang":[208],"PNAS.":[211],"2021;":[212],"Bi":[213],"Immunity.":[216],"2025;":[217],"Hugaboom":[218],"Discovery.":[222],"2025),":[223],"including":[224,498,515,590],"pre-":[226],"post-ICI":[228],"treatment":[229],"samples.":[230],"Patient":[231],"derived":[232],"xenograft":[233],"(PDX)":[234],"models":[235,488],"generated":[237],"human":[239],"treated":[243],"first-in-class":[246],"inhibitor.":[248],"Gene":[249,300],"readouts":[251],"NanoString":[257],"nCounter":[258],"gene":[259],"array.":[261],"Results":[262],"Within":[263],"TCGA":[264],"KIRC,":[265],"significantly":[269,286,317,366,416],"increased":[270,287,367],"tissues":[274],"compared":[275,293,371,423,473],"matched":[277],"normal":[278,342],"kidney":[279],"epithelium":[280,344],"(p":[281,297,375,398],"<":[282,298,399],"0.0001)":[283],"Stage":[289,295],"IV":[290],"I":[296],"0.05).":[299],"set":[301],"enrichment":[302,306,348],"revealed":[304],"significant":[305],"adaptive":[308],"processes":[310],"tumors;":[313],"also":[316,392],"correlated":[318],"molecules":[324],"predicted":[326],"infiltration":[327],"numerous":[329],"pro-inflammatory":[330,494],"populations":[332],"deconvolution.":[335],"scRNAseq":[336,435],"adjacent":[341],"confirmed":[346],"tumor-infiltrating":[350],"populations,":[352],"highest":[354],"proliferating":[357],"lymphocytes.":[358],"In":[359],"cohorts,":[362],"PD-L1+":[369],"PD-L1-":[373],"=":[376,429,432,445,471,479],"5.85x10-5":[377],"7.35x10-7":[379],"respectively).":[384],"T-Effector/Proliferative":[387],"cluster":[390],"disproportionately":[393],"cases":[397],"0.00001).":[400],"status":[402],"did":[403,414,464,477],"not":[404,465],"predict":[405],"improved":[406],"outcomes":[407],"either":[409],"atezolizumab/bevacizumab":[410],"or":[411,525,579],"avelumab/axitinib":[412],"but":[413],"portend":[415],"prolonged":[417],"free":[419],"survival":[420],"nivolumab":[422,469],"GPR65-Low":[425],"HCRN-GU16-260":[427],"(HR":[428],"0.49,":[430],"p":[431],"0.009).":[433],"post-progression":[438],"specimens":[440],"four":[442],"(n":[444,470,478],"21,521":[446],"cells)":[447],"demonstrated":[448],"appreciable":[450],"increase":[451],"amongst":[455],"myeloid":[456],"natural":[458],"killer":[459],"achieve":[466],"response":[467],"2)":[472,480],"those":[475],"HCRN-GU16-260.":[482],"PDX":[487],"led":[489],"heightened":[491],"T":[495],"genes":[497,514],"IL2RG,":[499],"chemokines":[500],"(CCL4,":[501],"CCL5,":[502],"CXCL10),":[503],"antigen":[505],"processing":[506],"machinery":[507],"(PSMB7-10),":[508],"concurrent":[509],"suppression":[511],"pro-tumorigenic":[513],"TGFB":[516],"IL10":[518],"achieved":[520],"control":[522],"equivalent":[523],"surpassing":[526],"anti-PD-1":[527,583],"therapy":[528],"syngeneic":[530],"mouse":[531],"Conclusions":[533],"represents":[535],"clinically":[537],"actionable":[538],"biologically":[540],"relevant":[541],"target":[542,554],"These":[547],"suggest":[549],"rational":[553],"ICI-based":[561],"therapy.":[562],"ongoing":[564],"phase":[565],"I/II":[566],"RAISIC-1":[567],"(NCT06634849)":[569],"investigating":[571],"novel":[573],"inhibitor,":[575],"PTT-4256,":[576],"monotherapy":[578],"combination":[581],"ICI":[584],"tumors,":[589],"dose":[591],"expansion":[592],"RCC.":[597]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W7204995805","counts_by_year":[],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2026-09-02T00:00:00"}
